Acadia Pharma (ACAD) Misses Q1 View By 4c
Acadia Pharma (Nasdaq: ACAD) reports Q1 EPS of ($0.40), 4 cents below the analyst estimate of ($0.36). Revenue for the quarter was $374k, versus the consensus of $540K.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Synopsys, Inc. (SNPS) Misses Q2 EPS by 2c; Issues Confident Q3 Outlook; Guides FY12
- Infoblox (BLOX) Tops Q3 EPS by 4c; Guides Q4
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
